COVID‐19 and the peripheral nervous system. A 2‐year review from the pandemic to the vaccine era

Journal of the Peripheral Nervous System - Tập 27 Số 1 - Trang 4-30 - 2022
Arens Taga1, Giuseppe Lauria2,3
1Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
2Department of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
3Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy

Tóm tắt

AbstractIncreasing literature has linked COVID‐19 to peripheral nervous system (PNS) diseases. In addition, as we move from the pandemic to the vaccination era, literature interest is shifting towards the potential association between COVID‐19 vaccines and PNS manifestations. We reviewed published literature on COVID‐19, COVID‐19 vaccines and PNS manifestations between 1 January 2020 and 1 December 2021. For Guillain‐Barré syndrome (GBS), isolated cranial neuropathy (ICN) and myositis associated with COVID‐19, the demographic, clinical, laboratory, electrophysiological and imaging features were included in a narrative synthesis. We identified 169 studies on COVID‐19‐associated complications, including 63 papers (92 patients) on GBS, 29 papers (37 patients) on ICN and 11 papers (18 patients) on myositis. Additional clinical phenotypes included chronic inflammatory demyelinating polyneuropathy, vasculitic neuropathies, neuralgic amyotrophy, critical care‐related complications, and myasthenia gravis. PNS complications secondary to COVID‐19 vaccines have been reported during randomized clinical trials, in real‐world case reports, and during large‐scale surveillance programs. These mainly include cases of GBS, Bell's palsy, and cases of neuralgic amyotrophy. Based on our extensive review of the literature, any conclusion about a pathophysiological correlation between COVID‐19 and PNS disorders remains premature, and solely supported by their temporal association, while epidemiological and pathological data are insufficient. The occurrence of PNS complications after COVID‐19 vaccines seems limited to a possible higher risk of facial nerve palsy and GBS, to a degree that widespread access to the ongoing vaccination campaign should not be discouraged, while awaiting for more definitive data from large‐scale surveillance studies.

Từ khóa


Tài liệu tham khảo

10.1007/s11739-020-02379-z

10.1212/WNL.0000000000009937

10.1111/joim.13089

10.1159/000513647

10.1001/jamaneurol.2020.1127

10.1007/s00415-020-10251-5

10.1016/S2215-0366(20)30287-X

10.1212/WNL.0000000000010979

10.1212/WNL.0000000000010034

10.1056/NEJMc2031085

10.1111/jns.12419

10.1007/s00415-020-10124-x

10.1002/jmv.25728

10.1001/jamaneurol.2020.2065

10.1016/j.autneu.2020.102734

10.1016/j.jns.2020.117090

10.1016/j.jns.2021.117316

10.1186/s12974-021-02339-0

Lou JJ, 2021, Neuropathology of COVID‐19 (neuro‐COVID): clinicopathological update, Free Neuropathol, 2, 2

10.1016/S1474-4422(20)30308-2

10.1002/jmv.25915

10.1001/jamaoto.2020.2366

10.1212/WNL.0000000000012344

10.1001/jamainternmed.2020.6278

10.1056/NEJMra2026131

10.1161/STROKEAHA.120.031224

10.1007/s10072-021-05197-z

10.1016/j.clinimag.2020.11.017

10.1002/mus.27083

10.1002/mus.27035

10.1007/s00415-020-10108-x

10.1038/s41577-020-00458-y

10.1093/brain/awaa433

10.3390/dermatopathology7030010

10.1016/S2352-3026(20)30217-9

10.1111/ene.14388

10.1016/S1474-4422(20)30109-5

10.1016/j.clinph.2020.05.003

10.1016/j.neurol.2020.04.003

10.1111/jns.12382

10.1016/j.jneuroim.2020.577294

10.1212/NXI.0000000000000741

10.1007/s10072-020-04449-8

10.1007/s00415-020-09849-6

10.1007/s00415-020-09907-z

10.1016/j.nrl.2020.04.007

10.7861/clinmed.2020-0213

10.1016/j.medin.2020.08.009

10.1002/mus.26988

10.1136/bcr-2020-236182

10.1136/bcr-2020-236536

10.1016/j.bbi.2020.04.074

10.1007/s00415-020-09911-3

10.1136/bcr-2020-239241

10.1093/jpids/piaa086

10.1212/NXI.0000000000000785

10.1007/s10072-020-04484-5

10.1002/mus.26992

10.1017/cjn.2020.106

10.1007/s10072-020-04553-9

10.1111/ene.14398

Garcia‐Manzanedo S, 2020, Guillain‐Barre syndrome after Covid‐19 infection, Med Clin (Engl Ed), 155, 366

10.1111/ene.14383

10.1007/s00415-020-10014-2

10.34172/icnj.2020.18

Ebrahimzadeh SA, 2021, Guillain‐Barré syndrome associated with the coronavirus disease 2019 (COVID‐19), Neurology Clin Pract

10.1056/NEJMc2009191

10.1002/jmv.26289

10.1186/s42466-020-00066-0

10.1016/j.mayocp.2020.05.029

10.1093/brain/awaa240

10.1007/s00415-020-09897-y

10.1097/CND.0000000000000309

Amira Sidig K. A HussienAbbasher MohammedAbbasher AbbasherHussien.COVID‐19 and Guillain‐Barre syndrome case report. doi:10.21203/rs.3.rs-48327/v1(2020).

10.1111/ene.14368

10.1016/j.neurol.2020.04.007

10.1016/j.jocn.2020.04.062

10.3389/fneur.2020.00909

10.1016/j.jocn.2020.11.013

10.1093/tropej/fmaa044

10.1097/CND.0000000000000322

10.1002/jmv.26121

Hutchins KL, 2020, COVID‐19‐associated bifacial weakness with paresthesia subtype of Guillain‐Barre syndrome, AJNR Am J Neuroradiol, 41, 1707

10.1016/j.neucli.2020.09.007

10.1097/NRL.0000000000000291

10.1016/j.nrl.2020.04.004

10.1016/j.idcr.2020.e00771

10.1007/s13365-020-00884-7

10.1002/ccr3.3397

10.3174/ajnr.A6609

10.1007/s00415-020-09912-2

10.1212/CPJ.0000000000000880

10.1212/WNL.0000000000009619

10.1007/s13365-020-00858-9

10.1016/j.bbih.2021.100203

10.1212/WNL.0000000000009700

10.1007/s13365-020-00908-2

Singh R, 2021, Association of Guillain‐Barre syndrome with COVID‐19: a case report and literature review, Cureus, 13, e13828

10.1136/jnnp-2020-324837

10.1002/ana.25987

10.1056/NEJMoa1605564

10.1159/000184748

10.1056/NEJMra1114525

10.1038/nrneurol.2014.121

10.1016/S0140-6736(16)00339-1

10.1159/000438752

10.1016/j.neucli.2021.02.001

10.1186/1471-2377-13-95

10.1111/jns.12439

10.1093/brain/awab279

10.1016/j.jmii.2020.05.017

10.1016/S0140-6736(20)31525-7

10.1007/s13760-021-01600-w

10.1001/jamaophthalmol.2020.5695

10.12659/AJCR.925897

10.1007/s00415-020-09773-9

10.2169/internalmedicine.5014-20

10.1136/bcr-2020-240095

10.1212/WNL.0000000000009863

10.1111/ene.14493

10.1007/s13365-020-00912-6

10.1002/ccr3.3631

10.1002/ccr3.3716

10.1136/bcr-2020-240267

10.1111/ene.14561

10.12659/AJCR.927956

10.1016/j.jocn.2020.05.016

10.1080/00207454.2020.1869001

10.1016/j.xocr.2020.100198

10.1016/j.ijid.2020.06.023

10.1016/j.mayocp.2020.05.034

10.1212/WNL.0000000000010011

10.1007/s10072-021-05087-4

10.1097/PHM.0000000000001607

10.1097/WNO.0000000000001146

10.1007/s00405-020-05965-1

10.1002/hed.26204

10.1001/jamaneurol.2020.2125

10.1016/S0140-6736(20)31014-X

10.1136/bjophthalmol-2020-317576

10.1111/aos.14734

10.1016/j.eclinm.2020.100550

10.1002/brb3.1939

10.1097/PEC.0000000000002231

10.1016/j.amjoto.2021.102956

10.1080/14992027.2020.1798519

10.1212/WNL.0b013e3181e07d14

10.1016/j.jns.2020.117106

10.1007/s00415-021-10417-9

10.1016/S2665-9913(20)30420-3

10.1007/s00415-020-10321-8

Enrique Estévez‐Rivera JB‐H, 2020, Mononeuritis multiplex associated with Sars‐Cov2‐Covid‐19 Infection: case report, Int J Neurol Neurother, 7

Soliman SB, 2020, Peripheral polyneuropathy associated with COVID‐19 in two patients: A musculoskeletal ultrasound case report, J Med Ultrasound, 28, 249, 10.4103/JMU.JMU_150_20

10.1136/bcr-2020-237459

Haroun MW, 2021, Rhabdomyolysis in COVID‐19 patients: a retrospective observational study, Cureus, 13, e12552

10.1177/03000605211061035

10.1136/bcr-2020-237616

10.1136/annrheumdis-2020-217573

Zhang Q, 2020, A rare presentation of coronavirus disease 2019 (COVID‐19) induced viral myositis with subsequent rhabdomyolysis, Cureus, 12, e8074

10.1002/mus.27003

Gokhale Y, 2020, Dermatomyositis during COVID‐19 Pandemic (a case series): is there a cause effect relationship?, J Assoc Physicians India, 68, 20

10.3174/ajnr.A6711

10.1016/j.jvscit.2020.08.021

10.1186/s13395-021-00266-5

Kitamura M, 2021, Clinically amyopathic dermatomyositis during the COVID‐19 pandemic, Oxf Med Case Reports, 061, 2021

10.1186/s12890-020-01335-z

10.1111/his.14160

Sriwastava S, 2020, New onset of ocular myasthenia gravis in a patient with COVID‐19: a novel case report and literature review, J Neurol

10.7326/L20-0845

10.3389/fneur.2020.576153

10.7326/L20-1298

10.1111/ene.14721

10.1002/mus.27020

10.1002/mus.26918

10.3389/fneur.2020.01053

10.1136/jnnp-2020-323565

10.1016/j.jns.2021.117362

10.1016/S1474-4422(20)30413-0

10.1002/mus.27324

10.1212/WNL.0000000000011669

10.1111/ane.13440

10.1016/j.clinph.2020.09.017

10.1212/WNL.0000000000010280

10.1186/s12879-020-05507-4

10.3892/etm.2021.10616

10.1056/NEJMoa1214103

10.1016/j.bja.2020.08.045

10.1016/j.apmr.2020.10.131

10.1093/ptj/pzaa191

10.2106/JBJS.CC.20.00729

10.1002/mus.27055

10.1002/mus.27202

10.1186/s13054-020-03289-4

10.1038/s41591-021-01283-z

Carod‐Artal FJ, 2021, Post‐COVID‐19 syndrome: epidemiology, diagnostic criteria and pathogenic mechanisms involved, Rev Neurol, 72, 384

10.1001/jama.2021.3331

10.1038/s41591-021-01433-3

10.1093/brain/awab009

10.1093/braincomms/fcaa205

10.1097/PR9.0000000000000893

10.1002/jcsm.12681

10.1001/jama.2020.12603

10.1007/s12026-021-09185-5

10.7861/clinmed.2020-0896

10.1007/s10286-021-00803-8

10.1016/j.neucli.2021.01.003

Abrams RMC, 2021, Small fiber neuropathy associated with SARS‐CoV‐2 infection, Muscle Nerve

10.1016/j.mayocp.2021.07.004

10.1136/bmj.38933.585764.AE

10.1056/NEJMoa2034577

10.1056/NEJMoa2035389

10.1056/NEJMoa2034201

10.1016/S0140-6736(20)32661-1

10.1016/S0140-6736(21)00234-8

10.1056/NEJMoa2107659

10.1001/jama.2020.15543

10.15585/mmwr.mm7043e2

10.15585/mmwr.mm7027e2

10.1056/NEJMoa2110737

10.2165/00002018-200932040-00005

10.1212/WNL.0000000000011881

10.1016/j.neurol.2021.04.005

10.1016/j.idcr.2021.e01143

10.1136/bcr-2021-243629

10.1136/bcr-2021-242956

10.18071/isz.74.0286

Waheed S, 2021, Neurological complications of COVID‐19: Guillain‐Barre syndrome following Pfizer COVID‐19 vaccine, Cureus, 13, e13426

10.1016/j.amsu.2021.102540

10.1007/s10072-021-05467-w

Bonifacio GB, 2021, Bilateral facial weakness with paraesthesia variant of Guillain‐Barre syndrome following Vaxzevria COVID‐19 vaccine, J Neurol Neurosurg Psychiatry

10.1136/bcr-2021-244125

10.1111/ncn3.12537

10.1007/s10072-021-05523-5

10.1080/21645515.2021.1954826

10.1016/j.jneuroim.2021.577719

10.1016/j.jneuroim.2021.577691

10.1002/mus.27461

10.1002/ana.26144

10.1002/ana.26143

10.1001/jama.2021.16496

10.1038/s41591-021-01556-7

10.3201/eid2712.211634

10.1016/j.clim.2021.108818

10.1001/jama.2021.15072

10.1016/j.jaut.2021.102662

10.1093/brain/awaa444

10.1159/000324710

10.1016/S1473-3099(21)00076-1

10.1007/s00415-021-10462-4

10.1016/j.bbih.2021.100217

10.1136/bcr-2021-243829

Shemer A, 2021, Peripheral facial nerve palsy following BNT162b2 (COVID‐19) vaccination, Isr Med Assoc J, 23, 143

10.4103/ijo.IJO_2122_21

10.1016/j.jaapos.2021.05.003

10.4103/ijo.IJO_1968_21

Manea MM, 2021, Multiple cranial nerve palsies following COVID‐19 vaccination‐case report, Acta Neurol Scand

10.1186/s12883-021-02489-x

10.4161/hv.27032

Abdelrhman Abo‐Zed AP, 2021, Guillain‐Barré syndrome, or acute on chronic inflammatory demyelinating polyneuropathy, following Moderna Covid‐19 vaccine, Chest, 160, S1

10.1136/bcr-2021-245816

10.1111/ene.14044

10.1111/j.1529-8027.2009.00243.x

10.1136/jnnp.73.3.348

Hughes RA, 1996, Immunization and risk of relapse of Guillain‐Barre syndrome or chronic inflammatory demyelinating polyradiculoneuropathy, Muscle Nerve, 19, 1230

Victoria Chisholm NB, 2021, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and vaccinations: examining the current literature on vaccinations and the onset or worsening of CIDP symptoms, touchNeurology, 17, 3

10.1001/jama.2021.7517

10.2106/JBJS.CC.21.00370

10.1093/qjmed/hcab216

10.1002/mus.27255

10.1186/s13256-021-03176-8

10.1002/pmrj.12619

10.1177/03000605211056783

10.1016/j.nrl.2021.05.007

10.1148/radiol.2021211374

10.1001/jama.2021.5374

10.1016/j.dsx.2021.06.007

Mack M, 2021, Rhabdomyolysis secondary to COVID‐19 vaccination, Cureus, 13, e15004

10.1093/qjmed/hcab043

10.1093/qjmed/hcab161

10.1007/s00415-021-10768-3

10.1016/S1473-3099(21)00460-6

10.1177/003591576505800503

10.1007/s10072-020-04540-0

10.1001/jamaneurol.2021.3287

10.1002/mus.27179

10.1111/jns.12435

Thông tin
Thông tin xuất bản

Journal of the Peripheral Nervous System

Tập 27 Số 1

4-30

Thông tin tác giả